JP2016523260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523260A5 JP2016523260A5 JP2016521898A JP2016521898A JP2016523260A5 JP 2016523260 A5 JP2016523260 A5 JP 2016523260A5 JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016523260 A5 JP2016523260 A5 JP 2016523260A5
- Authority
- JP
- Japan
- Prior art keywords
- pruritus
- serlopitant
- octahydroisoindol
- cyclopent
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000003251 Pruritus Diseases 0.000 claims 2
- ZKBUZTAYJPNYSH-INPQDFLLSA-N (3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-(cyclopenten-1-yl)-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindole Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)[C@@H](C)O[C@@H]1[C@H]([C@@H]2CN(C[C@H]2CC1)C1=CCCC1)C1=CC=C(C=C1)F)(F)F ZKBUZTAYJPNYSH-INPQDFLLSA-N 0.000 claims 1
- FLNYCRJBCNNHRH-OIYLJQICSA-N 3-[(3ar,4r,5s,7as)-5-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one Chemical compound C1([C@H]2[C@@H]3CN(C[C@H]3CC[C@@H]2O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2CCC(=O)C=2)=CC=C(F)C=C1 FLNYCRJBCNNHRH-OIYLJQICSA-N 0.000 claims 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950011343 serlopitant Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838784P | 2013-06-24 | 2013-06-24 | |
| US13/925,509 US8906951B1 (en) | 2013-06-24 | 2013-06-24 | Use of NK-1 receptor antagonists in pruritus |
| US61/838,784 | 2013-06-24 | ||
| US13/925,509 | 2013-06-24 | ||
| PCT/US2014/043811 WO2014209962A1 (en) | 2013-06-24 | 2014-06-24 | Use of nk-1 receptor antagonist serlopitant in pruritus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087897A Division JP2019142960A (ja) | 2013-06-24 | 2019-05-07 | そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016523260A JP2016523260A (ja) | 2016-08-08 |
| JP2016523260A5 true JP2016523260A5 (hr) | 2017-08-03 |
Family
ID=51230173
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521898A Ceased JP2016523260A (ja) | 2013-06-24 | 2014-06-24 | そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 |
| JP2019087897A Pending JP2019142960A (ja) | 2013-06-24 | 2019-05-07 | そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087897A Pending JP2019142960A (ja) | 2013-06-24 | 2019-05-07 | そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3013336A1 (hr) |
| JP (2) | JP2016523260A (hr) |
| KR (1) | KR20160023692A (hr) |
| CN (1) | CN105473138A (hr) |
| AU (2) | AU2014302694B2 (hr) |
| BR (1) | BR112015031724A2 (hr) |
| CA (1) | CA2915474A1 (hr) |
| HK (1) | HK1223820A1 (hr) |
| IL (1) | IL243189A0 (hr) |
| MX (2) | MX366728B (hr) |
| PH (2) | PH12015502777A1 (hr) |
| RU (1) | RU2666219C2 (hr) |
| WO (1) | WO2014209962A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| KR102424837B1 (ko) | 2014-09-19 | 2022-07-25 | 헤론 테라퓨틱스 인코포레이티드 | 아프레피탄트의 에멀젼 제형 |
| RU2770050C2 (ru) | 2015-03-04 | 2022-04-14 | Ванда Фармасьютиклз Инк. | Способ лечения с применением традипитанта |
| CN108883058A (zh) * | 2016-02-01 | 2018-11-23 | 赫伦治疗有限公司 | 含有nk-1受体拮抗剂的乳剂 |
| US9974742B2 (en) | 2016-02-01 | 2018-05-22 | Heron Therapeutics, Inc. | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
| BR112018077300A2 (pt) * | 2016-06-29 | 2019-04-02 | Menlo Therapeutics Inc. | uso de antagonistas de neurocinina-1 para tratar diversas condições pruríticas |
| US11549147B2 (en) * | 2017-09-13 | 2023-01-10 | Vanda Pharmaceuticals Inc. | Treatment of atopic dermatitis with tradipitant |
| SG11202003886TA (en) * | 2017-11-01 | 2020-05-28 | Nat Univ Singapore | Use of serotonergic drugs to treat virus-induced thrombocytopenia |
| WO2019152232A1 (en) * | 2018-01-31 | 2019-08-08 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
| CN115015440A (zh) * | 2022-07-08 | 2022-09-06 | 江苏杜瑞制药有限公司 | 一种生物样品中纳呋拉啡的检测方法 |
| CN117503699A (zh) * | 2023-12-08 | 2024-02-06 | 斯坦德医药研发(江苏)有限公司 | 阿瑞匹坦口服液制剂及制剂制造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030100565A1 (en) | 2001-09-21 | 2003-05-29 | Boehringer Ingelheim International Gmbh | Method for the treatment or prevention of atopic dermatitis |
| AR047439A1 (es) * | 2004-01-27 | 2006-01-18 | Merck & Co Inc | Antagonistas del receptor hidroisoindolina taquiquinina |
| CN100582093C (zh) * | 2004-01-27 | 2010-01-20 | 默克公司 | 氢异二氢吲哚速激肽受体拮抗剂 |
| WO2007008564A1 (en) | 2005-07-11 | 2007-01-18 | Merck & Co., Inc. | Process for making hydroisoindoline tachykinin receptor antagonists |
| WO2007044296A2 (en) | 2005-10-04 | 2007-04-19 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| WO2007146224A2 (en) | 2006-06-12 | 2007-12-21 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| CA2662435A1 (en) | 2006-09-06 | 2008-03-13 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| WO2008054690A2 (en) | 2006-11-02 | 2008-05-08 | Merck & Co., Inc. | Polymorphs of a hydroisoindoline tachykinin receptor antagonist |
| EP2141992A1 (en) | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
| RU2370265C1 (ru) * | 2008-03-04 | 2009-10-20 | Лев Давидович Раснецов | Гель, обладающий противовоспалительным и противоаллергическим действием |
-
2014
- 2014-06-24 BR BR112015031724A patent/BR112015031724A2/pt not_active Application Discontinuation
- 2014-06-24 WO PCT/US2014/043811 patent/WO2014209962A1/en active Application Filing
- 2014-06-24 CN CN201480035219.3A patent/CN105473138A/zh active Pending
- 2014-06-24 MX MX2015017763A patent/MX366728B/es active IP Right Grant
- 2014-06-24 RU RU2015154037A patent/RU2666219C2/ru active
- 2014-06-24 AU AU2014302694A patent/AU2014302694B2/en not_active Ceased
- 2014-06-24 KR KR1020157035921A patent/KR20160023692A/ko not_active Application Discontinuation
- 2014-06-24 JP JP2016521898A patent/JP2016523260A/ja not_active Ceased
- 2014-06-24 CA CA2915474A patent/CA2915474A1/en not_active Abandoned
- 2014-06-24 EP EP14744671.0A patent/EP3013336A1/en not_active Withdrawn
-
2015
- 2015-12-14 PH PH12015502777A patent/PH12015502777A1/en unknown
- 2015-12-17 IL IL243189A patent/IL243189A0/en unknown
- 2015-12-18 MX MX2019008643A patent/MX2019008643A/es unknown
-
2016
- 2016-09-23 HK HK16111172.9A patent/HK1223820A1/zh unknown
-
2019
- 2019-05-07 JP JP2019087897A patent/JP2019142960A/ja active Pending
-
2020
- 2020-01-14 AU AU2020200259A patent/AU2020200259A1/en not_active Abandoned
- 2020-02-04 PH PH12020500255A patent/PH12020500255A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523260A5 (hr) | ||
| JP2016034978A5 (hr) | ||
| JP2014156468A5 (hr) | ||
| JP2016518337A5 (hr) | ||
| JP2013519675A5 (hr) | ||
| JP2016515522A5 (hr) | ||
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| EP3589628A4 (en) | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES | |
| CY1118839T1 (el) | Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη | |
| JP2016535795A5 (hr) | ||
| EA201790630A1 (ru) | Способы получения рибозидов | |
| EP3607950A3 (en) | Hepatitis b core protein allosteric modulators | |
| JP2015024998A5 (hr) | ||
| EA201692436A1 (ru) | Медицинское применение | |
| JP2016539157A5 (hr) | ||
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| JP2015078220A5 (hr) | ||
| JP2013543896A5 (hr) | ||
| JP2013173781A5 (hr) | ||
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| HK1259405A1 (zh) | N-[5-(3，5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型 | |
| JP2016522254A5 (hr) | ||
| HRP20191121T1 (hr) | Tretman multiple skleroze | |
| JP2015199738A5 (hr) | ||
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου |